Are GLP-1 agonists the answer to our obesity epidemic?

Dapre examines whether GLP-1 agonists are the answer to the obesity epidemic. The number of people living with obesity in the UK has doubled since 1993 and continues to rise. Obesity is associated with various health risks and puts strain on the healthcare system. Current public health initiatives have not effectively addressed the root cause of obesity. GLP-1 agonists, which increase insulin production and decrease appetite, offer a potential solution. However, their long-term effectiveness is uncertain, and there are concerns about side effects and the lack of mental health benefits from exercise. He argues that a short-term weight loss fix using GLP-1 agonists without a comprehensive long-term plan is shortsighted. It calls for collaborative efforts and proactive measures to prevent obesity from the beginning, rather than relying on reactive solutions.